{"id":"NCT04294667","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-08-12","primaryCompletion":"2024-05-22","completion":"2024-06-04","firstPosted":"2020-03-04","resultsPosted":"2025-04-24","lastUpdate":"2025-05-04"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"DRUG","name":"DZP","otherNames":["CDP7657"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Dapirolizumab pegol","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.","primaryOutcome":{"measure":"Percentage of Participants With Achievement of BILAG 2004-based Composite Lupus Assessment (BICLA) Response at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"PBO+SOC","deltaMin":34.6,"sd":null},{"arm":"DZP+SOC","deltaMin":49.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0110"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":13},"locations":{"siteCount":177,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Chile","Colombia","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Mexico","Peru","Philippines","Poland","Romania","Serbia","South Korea","Spain","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":108},"commonTop":["COVID-19","Urinary tract infection","Nasopharyngitis","Upper respiratory tract infection","Diarrhoea"]}}